Ozempic and Mounjaro risks: what the evidence actually shows

The biggest misconception: that these two medicines carry identical risks

Most people searching this topic assume Ozempic and Mounjaro are near-identical because both are weekly injections used in weight management. The reality is more layered. Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) activates only the GLP-1 receptor and is licensed in the UK for type 2 diabetes, not weight loss. The licensed weight-loss options on the UK market are Wegovy (semaglutide 2.4 mg / 7.2 mg) and Mounjaro (tirzepatide), which additionally activates the GIP receptor. That dual mechanism changes not just the efficacy picture but also the nuance of how the body responds.

Practically, both medicines slow gastric emptying and reduce appetite through gut-hormone pathways, so their most common side effects overlap substantially. But the doses at which each is used differ, the receptor targets differ, and the licensed indications differ. Treating them as interchangeable when weighing risks misses something clinically important.

The tirzepatide vs Ozempic side-effect comparison goes into granular trial-level detail; this page focuses on the shared and divergent risk patterns, and on what either finding means for someone considering weight management in the UK.

Where the risk profiles genuinely overlap

The dominant risk pattern for both medicines is gastrointestinal. Nausea, vomiting, diarrhoea, constipation, indigestion and burping are the most frequently reported effects in clinical trials and post-market data for both semaglutide and tirzepatide. These effects tend to be worst in the first few weeks and after each dose increase, and they typically ease as the body adjusts. Fatigue, headache and dizziness are also reported across both.

Pancreatitis is a known but infrequent risk with GLP-1 medicines broadly. In January 2026 the MHRA issued a Drug Safety Update specifically flagging acute pancreatitis for this medicine class, advising that severe, persistent stomach pain radiating to the back (with or without vomiting) warrants urgent medical attention. That warning applies equally to semaglutide and tirzepatide. You can report any suspected side effects at the MHRA's Yellow Card scheme.

Gallbladder-related symptoms, allergic reactions, and dehydration from prolonged GI illness are shared concerns documented in the prescribing information for both medicines. The Mounjaro and Wegovy side-effects page covers the clinical management of these effects in more depth.

Where the risks differ between the two

The GIP receptor component in tirzepatide creates some distinctions. One that carries everyday practical weight: women taking oral contraceptives should add a non-oral method of contraception for the first four weeks of Mounjaro treatment and for four weeks after each dose increase, because gastric-emptying changes can reduce pill absorption. The NHS has noted no equivalent evidence for reduced oral contraceptive effectiveness with semaglutide. This matters if you are managing your contraception alongside starting treatment.

Dose titration schedules also differ. Mounjaro starts at 2.5 mg (a dose whose job is adjustment, not weight loss) and steps up through six possible strengths to 15 mg. Semaglutide in its weight-loss form (Wegovy) starts at 0.25 mg and climbs to 2.4 mg or, since MHRA approval in April 2026, 7.2 mg. If you are weighing up how the side-effect profiles of these two medicines compare in practice, our page on Wegovy vs Mounjaro side effects sets out the differences in detail. The NHS provides detailed side-effect information for tirzepatide on its medicines pages and separately for semaglutide, including what to do if GI effects are severe.

On the effectiveness side, the SURMOUNT-5 trial published in the New England Journal of Medicine (2025) found tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks in adults with obesity who did not have diabetes. That efficacy advantage does not necessarily mean a worse safety profile, but it does mean the medicines are not equivalent in how they act, and a prescriber weighs both sides.

What is actually licensed for weight loss in the UK, and what to do next

Ozempic is not the weight-management option here. Using it outside its licensed indication for weight loss would require a prescriber to deviate from its authorised use, and it is not something a regulated UK pharmacy would dispense for that purpose. The licensed choices for weight management are Wegovy (semaglutide in the weight-loss dose) and Mounjaro (tirzepatide). Anyone comparing these two medicines and wanting to understand how their tolerability profiles differ in more detail will find our page on Wegovy v Mounjaro side effects a useful reference, alongside the Wegovy vs Mounjaro page, which covers how trial results translate to real-world eligibility discussions.

The table below sets out the key risk-relevant facts side by side.

Both medicines require the same clinical starting point: an assessment by a prescriber who knows your full health picture. Which suits you is a clinical decision our prescribers make with you. For a fuller picture of how the two medicines compare on tolerability, our page on Ozempic vs Mounjaro side effects is worth reading before your consultation. If you want to explore whether Mounjaro or Wegovy might be right for your situation, the free consultation with our clinical team is the place to start, a real prescriber reads your answers the same day, no algorithm involved. You can also browse common questions or read more about how nume works.